CORE E: NOVEL TARGET DISCOVERY AND ASSAY

核心 E：新靶标发现和测定

• 批准号: 9066639
• 负责人: Julian P Whitelegge
• 金额: $ 21.67万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-05-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9066639
• 关键词: Address; Animal Experiments; Binding; Bioinformatics; Biological; Biological Assay; Biological Markers; Biological Process; Biology; Cells; Clinic; Clinical; Communication; Complement; Complications of Diabetes Mellitus; Computer software; Consult; Continuing Education; Data; Data Analyses; Data Discovery; Databases; Development; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Epigenetic Process; Foundations; Funding; GHR gene; Genetic; Genomics; Goals; Homologous Gene; Human; Human Genetics; Individual; Inflammatory; Institutes; Insulin; Insulin Resistance; Insulin-Like Growth-Factor-Binding Proteins; Ions; Knockout Mice; Label; Lead; Leadership; Learning; Length; Mass Spectrum Analysis; Measurement; Measures; Metabolic; Metabolism; Mission; Molecular; Monitor; Mus; Obesity; Patient-Focused Outcomes; Patients; Peptides; Performance; Physiology; Post-Translational Protein Processing; Prevention; Protein Analysis; Protein Isoforms; Proteins; Proteomics; Qualifying; Quality Control; Reaction; Reagent; Research; Research Personnel; Resolution; Resources; Sampling; Services; Signal Transduction; Stable Isotope Labeling; Statistical Data Interpretation; Strategic Planning; Structure; System; Testing; Transgenic Organisms; Translating; Translations; Validation; assay development; biological systems; candidate marker; clinical assay development; clinically relevant; combat; community center; cost effective; data mining; design; empowered; experience; high throughput screening; humanin; improved; interest; mass spectrometer; meetings; member; nano-liquid chromatography; novel; novel therapeutics; outreach; polyclonal antibody; research study; scaffold; statistics; synthetic peptide; tandem mass spectrometry

The Novel Target Discovery and Assay Development Core (NTDAC) will provide investigators at UCLA, UCSD, the Salk Institute and Cedars-Sinai with consultancy and a suite of state-of-the-art molecular measurements not available from other national resources. The new NTDAC core assembles a comprehensive and highly specialized core with expertize in biological mass spectrometry and proteomics (Julian Whitelegge, Director) and ELISA assay development (Pinchas Cohen, Co-Director). Strengths of this biomedical core include the extensive expertise ofthe core leadership in diabetes research, wide experience in protein and peptide analysis, access to bioinformatics resources, and the collegial outreach of NTDAC leadership to DRC investigators to assist in the strategic planning and execution of studies relevant to the DRC mission. Core goals include: 1) provide an accessible user interface toward meeting objectives in a timely, cost effective, and integrated manner individualized to the specific needs of each DRC investigator, 2) provide discovery mass spectrometry services with appropriate bioinformatics for sensitive, accurate measurements with quality control, 3) provide biomarker qualification, immunocapture and top-down mass spectrometry for qualification of lead proteins and peptides with respect to biological function, 4) provide assay construction for novel peptides and proteins, and optimization of reliable assays toward the clinic, 5) provide ELISA services for novel assays for development of new clinical assays for better patient outcomes in diabetes. The collective and complementary expertise of the core leadership is outstanding and provides DRC investigators with an opportunity to explore and implement experimental strategies that rely upon direct analysis of proteins and peptides. The new NTDAC core provides discovery proteomics and peptidomics, alongside the lipidomics component that has been introduced into the MMPC (core B). The core will synergize with the other DRC cores through many favorable interactions including identification of interaction partners (core A), integration with metabolism and physiology studies (core B) and enhanced bioinformatics resources related to the genomics and genetics cores (C & D). Collectively, our ability to study the proteins and peptides of insulin action, substrate metabolism, and inflammatory signaling will drive the UCSD-UCLA DRC forward in discovery of critical biological molecules involved in the pathobiology of obesity and insulin resistance, and provide a foundation for the development of novel therapeutic strategies to combat diabetes and diabetes complications.

新目标发现和检测开发核心（NTDAC）将为加州大学洛杉矶分校，加州大学圣地亚哥分校，索尔克研究所和Cedars-Sinai的研究人员提供咨询和一套其他国家资源无法提供的最先进的分子测量。新的NTDAC核心汇集了一个全面和高度专业化的核心，在生物质谱和蛋白质组学（Julian Whitelegge，主任）和ELISA检测开发（Pinchas Cohen，联合主任）方面具有专业知识。这个生物医学核心的优势包括糖尿病研究核心领导层的广泛专业知识，蛋白质和肽分析的广泛经验，生物信息学资源的获取，以及NTDAC领导层对DRC研究人员的合议外展，以协助DRC使命相关研究的战略规划和执行。核心目标包括：1）提供可访问的用户界面，以及时、成本有效和集成的方式满足每个DRC研究者的特定需求，2）提供具有适当生物信息学的发现质谱服务，用于灵敏、准确的测量和质量控制，3）提供生物标志物鉴定，免疫捕获和自上而下质谱法用于鉴定先导蛋白质和肽生物学功能，4）提供新肽和蛋白质的测定构建，和优化可靠的临床分析，5）为开发新的临床分析提供ELISA服务，以改善糖尿病患者的预后。核心领导层的集体和互补的专业知识是杰出的，为DRC研究人员提供了探索和实施依赖于蛋白质和肽直接分析的实验策略的机会。新的NTDAC核心提供发现蛋白质组学和肽组学，以及已引入MMPC（核心B）的脂质组学组件。该核心将通过许多有利的相互作用与其他DRC核心协同，包括相互作用伙伴的鉴定（核心A），与代谢和生理学研究的整合（核心B）以及与基因组学和遗传学核心相关的增强的生物信息学资源（C & D）。总的来说，我们研究胰岛素作用、底物代谢和炎症信号传导的蛋白质和肽的能力将推动UCSD-UCLA DRC在发现肥胖和胰岛素抵抗的病理生物学中涉及的关键生物分子方面向前发展，并为开发新的治疗策略以对抗糖尿病和糖尿病并发症提供基础。